• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接受阿杜卡单抗治疗的APOE ε4/ε4患者中出现的有症状的淀粉样蛋白相关成像异常。

Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.

作者信息

VandeVrede Lawren, Gibbs Daniel M, Koestler Mary, La Joie Renaud, Ljubenkov Peter A, Provost Karine, Soleimani-Meigooni David, Strom Amelia, Tsoy Elena, Rabinovici Gil D, Boxer Adam L

机构信息

Memory and Aging Center Department of Neurology University of California San Francisco San Francisco California USA.

Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco California USA.

出版信息

Alzheimers Dement (Amst). 2020 Oct 9;12(1):e12101. doi: 10.1002/dad2.12101. eCollection 2020.

DOI:10.1002/dad2.12101
PMID:33072846
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7545921/
Abstract

INTRODUCTION

Amyloid-related imaging abnormalities (ARIA) are a common, dose-dependent effect of amyloid-targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.

METHODS

We describe the clinical course and management of a 66-year-old white male (APOE ε4/ε4) enrolled in an observational study that included amyloid and tau positron emission tomography (PET), who received aducanumab through the ENGAGE clinical trial.

RESULTS

Acute symptoms included headache and encephalopathy, and magnetic resonance imaging revealed ARIA-E and ARIA-H. Malignant hypertension and epileptiform activity were treated with nicardipine and levetiracetam. Subsequent clinical/imaging worsening prompted a course of methylprednisolone. Symptoms and ARIA-E resolved over 6 months, while ARIA-H persisted. Quantitative analysis of interval amyloid PET showed reduced signal in pre-existing areas but increased signal posteriorly; while tau PET showed increased signal overall.

DISCUSSION

In an APOE ε4/ε4 patient, ARIA symptoms were accompanied by malignant hypertension and epileptiform activity, and pulsed steroids reversed edema. Studies from larger cohorts may clarify the optimal treatment and pathophysiology of ARIA.

摘要

引言

淀粉样蛋白相关成像异常(ARIA)是靶向淀粉样蛋白抗体常见的剂量依赖性效应,与载脂蛋白E(APOE)ε4等位基因密切相关。

方法

我们描述了一名66岁白人男性(APOE ε4/ε4)的临床病程及治疗情况,该患者参与了一项包含淀粉样蛋白和tau正电子发射断层扫描(PET)的观察性研究,并通过ENGAGE临床试验接受了阿杜卡单抗治疗。

结果

急性症状包括头痛和脑病,磁共振成像显示有ARIA-E和ARIA-H。恶性高血压和癫痫样活动分别用尼卡地平和左乙拉西坦治疗。随后的临床/影像学恶化促使采用甲泼尼龙治疗。症状和ARIA-E在6个月内消退,而ARIA-H持续存在。对期间淀粉样蛋白PET的定量分析显示,先前存在的区域信号降低,但后部信号增加;而tau PET显示总体信号增加。

讨论

在一名APOE ε4/ε4患者中,ARIA症状伴有恶性高血压和癫痫样活动,脉冲式类固醇治疗可逆转水肿。来自更大队列的研究可能会阐明ARIA的最佳治疗方法和病理生理学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b333/7545921/68b39a89bff0/DAD2-12-e12101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b333/7545921/bac06b309979/DAD2-12-e12101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b333/7545921/68b39a89bff0/DAD2-12-e12101-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b333/7545921/bac06b309979/DAD2-12-e12101-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b333/7545921/68b39a89bff0/DAD2-12-e12101-g002.jpg

相似文献

1
Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.在接受阿杜卡单抗治疗的APOE ε4/ε4患者中出现的有症状的淀粉样蛋白相关成像异常。
Alzheimers Dement (Amst). 2020 Oct 9;12(1):e12101. doi: 10.1002/dad2.12101. eCollection 2020.
2
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.ARIA 的全基因组关联研究来自 aducanumab 三期 ENGAGE 和 EMERGE 研究。
Neurology. 2024 Feb 13;102(3):e207919. doi: 10.1212/WNL.0000000000207919. Epub 2023 Dec 28.
3
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.在两项评估早期阿尔茨海默病患者使用 aducanumab 的 3 期研究中,淀粉样蛋白相关成像异常。
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
4
Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.接受巴宾纽单抗治疗的阿尔茨海默病患者的淀粉样蛋白相关成像异常-含铁血黄素(ARIA-H):一项历史性前瞻性二次分析
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):106-12. doi: 10.1136/jnnp-2014-309493. Epub 2015 Feb 10.
5
Amyloid-Related Imaging Abnormalities and β-Amyloid-Targeting Antibodies: A Systematic Review.淀粉样蛋白相关成像异常与β淀粉样蛋白靶向抗体:一项系统综述。
JAMA Neurol. 2022 Mar 1;79(3):291-304. doi: 10.1001/jamaneurol.2021.5205.
6
Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.在认知正常的个体中,具有两个、一个和没有 APOE ε4 等位基因拷贝的情况下,对纤维状淀粉样-β负担、配对螺旋丝 tau 负担和萎缩进行脑成像测量。
Alzheimers Dement. 2020 Apr;16(4):598-609. doi: 10.1016/j.jalz.2019.08.195. Epub 2020 Jan 16.
7
-ε4 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapy.阿尔茨海默病临床试验中安慰剂组报告的与ε4等位基因相关的不良事件:对抗淀粉样β蛋白治疗的启示
Front Dement. 2024 Jan 15;2:1320329. doi: 10.3389/frdem.2023.1320329. eCollection 2023.
8
Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report.皮质脊髓束的皮质下信号改变。急性可逆性后部白质脑病综合征的一种影像学表现:病例报告。
Radiol Case Rep. 2022 Nov 6;18(1):275-279. doi: 10.1016/j.radcr.2022.10.023. eCollection 2023 Jan.
9
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.接受加速批准的 aducanumab 治疗后出现淀粉样蛋白相关影像学异常的初步经验。
J Prev Alzheimers Dis. 2023;10(4):765-770. doi: 10.14283/jpad.2023.96.
10
Aducanumab: Appropriate Use Recommendations Update.阿杜卡奴单抗:合理使用建议更新。
J Prev Alzheimers Dis. 2022;9(2):221-230. doi: 10.14283/jpad.2022.34.

引用本文的文献

1
Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on Lecanemab.韩国老年精神医学协会阿尔茨海默病抗淀粉样蛋白单克隆抗体治疗实用指南:聚焦于乐卡奈单抗
J Korean Med Sci. 2025 Jul 21;40(28):e215. doi: 10.3346/jkms.2025.40.e215.
2
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics.用于早期阿尔茨海默病的莱卡奈单抗:法国记忆诊所联合会的合理使用建议
J Prev Alzheimers Dis. 2025 Apr;12(4):100094. doi: 10.1016/j.tjpad.2025.100094. Epub 2025 Feb 25.
3
Multi-functional role of apolipoprotein E in neurodegenerative diseases.

本文引用的文献

1
Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways.脑淀粉样血管病与阿尔茨海默病——一种肽,两种途径。
Nat Rev Neurol. 2020 Jan;16(1):30-42. doi: 10.1038/s41582-019-0281-2. Epub 2019 Dec 11.
2
Early Awareness of Alzheimer Disease: A Neurologist's Personal Perspective.阿尔茨海默病的早期认知:一位神经科医生的个人观点。
JAMA Neurol. 2019 Mar 1;76(3):249. doi: 10.1001/jamaneurol.2018.4910.
3
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.
载脂蛋白E在神经退行性疾病中的多功能作用。
Front Aging Neurosci. 2025 Jan 29;17:1535280. doi: 10.3389/fnagi.2025.1535280. eCollection 2025.
4
The global research of magnetic resonance imaging in Alzheimer's disease: a bibliometric analysis from 2004 to 2023.阿尔茨海默病磁共振成像的全球研究:2004年至2023年的文献计量分析
Front Neurol. 2025 Jan 15;15:1510522. doi: 10.3389/fneur.2024.1510522. eCollection 2024.
5
Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab.与接受 lecanemab 治疗的患者的淀粉样蛋白相关成像异常相关的缺血性脑卒中。
Alzheimers Dement. 2024 Nov;20(11):8192-8197. doi: 10.1002/alz.14223. Epub 2024 Aug 30.
6
Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities.阿尔茨海默病抗淀粉样蛋白免疫疗法:监测淀粉样蛋白相关影像异常的影像建议与实践考量
AJNR Am J Neuroradiol. 2025 Jan 8;46(1):24-32. doi: 10.3174/ajnr.A8469.
7
Developing a person-centered stated preference survey for dementia with Lewy bodies: value of a personal and public involvement process.为路易体痴呆症开展以患者为中心的陈述偏好调查:个人及公众参与过程的价值
Front Dement. 2024 Jul 15;3:1421556. doi: 10.3389/frdem.2024.1421556. eCollection 2024.
8
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation.ENTIMOS:决策支持工具通过临床情景模拟突出了多发性硬化症非静脉治疗对患者护理的潜在影响。
Pharmacoecon Open. 2024 Sep;8(5):755-764. doi: 10.1007/s41669-024-00493-8. Epub 2024 Jul 11.
9
Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy.淀粉样相关影像学异常(ARIA):淀粉样变修饰治疗中的诊断、管理和护理。
Ann Clin Transl Neurol. 2024 Jul;11(7):1669-1680. doi: 10.1002/acn3.52042. Epub 2024 Jun 28.
10
Epigenetic dysregulation in Alzheimer's disease peripheral immunity.阿尔茨海默病外周免疫中的表观遗传失调。
Neuron. 2024 Apr 17;112(8):1235-1248.e5. doi: 10.1016/j.neuron.2024.01.013. Epub 2024 Feb 9.
在轻度至中度阿尔茨海默病患者中进行的阿杜卡努单抗(BIIB037)首次人体、双盲、安慰剂对照、单剂量递增研究。
Alzheimers Dement (N Y). 2016 Jun 20;2(3):169-176. doi: 10.1016/j.trci.2016.06.002. eCollection 2016 Sep.
4
Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis.抗淀粉样蛋白-β免疫疗法治疗阿尔茨海默病的安全性和疗效:系统评价和荟萃分析。
J Neuroimmune Pharmacol. 2017 Mar;12(1):194-203. doi: 10.1007/s11481-016-9722-5. Epub 2016 Dec 26.
5
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.阿杜卡努单抗可减少阿尔茨海默病中的 Aβ 斑块。
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.
6
Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions.后部可逆性脑病综合征:临床和影像学表现、病理生理学及待解决的问题。
Lancet Neurol. 2015 Sep;14(9):914-925. doi: 10.1016/S1474-4422(15)00111-8. Epub 2015 Jul 13.
7
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.阿尔茨海默病患者接受 bapineuzumab 治疗后的淀粉样相关影像异常:一项回顾性分析。
Lancet Neurol. 2012 Mar;11(3):241-9. doi: 10.1016/S1474-4422(12)70015-7. Epub 2012 Feb 3.
8
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.淀粉样蛋白相关成像异常在淀粉样蛋白修饰治疗试验中的研究:来自阿尔茨海默病协会研究圆桌工作组的建议。
Alzheimers Dement. 2011 Jul;7(4):367-85. doi: 10.1016/j.jalz.2011.05.2351.